NCT07657052Enrolling By Invitation不适用
A Multicenter, Open-label Study Evaluating the Long-term Safety and Efficacy of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
S-INFINITY Pharmaceuticals Co., Ltd1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2025年8月15日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 26
- 试验地点
- 1
研究概览
简要总结
This is a multicenter, open-label study to evaluate the long-term safety and efficacy of XH-S003 capsules in PNH patients. About 26 PNH patients who had received and completed XH-S003 study treatment will be enrolled to take XH-S003 capsules orally according to protocol. Eligible subjects can maintain XH-S003 treatment until the end of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PNH patients who have previously received and completed the XH-S003 study treatment, and according to the investigator's evaluation, the benefits of treatment outweigh risks and may benefit from continued treatment with XH-S003;
- •Subjects who have been vaccinated against Neisseria meningitidis and Streptococcus pneumoniae as required by previous studies (if the vaccine protection period does not cover the duration of this study, timely booster vaccinations should be administered according to vaccination guidelines and local vaccination requirements);
排除标准
- •. History of malignancy in any organ or system within the past 5 years prior to screening (excluding localized basal cell carcinoma of the skin or in situ cervical cancer);
- •History of bone marrow/hematopoietic stem cell or solid organ transplantation;
- •History of splenectomy;
- •History of serious comorbidities , including but not limited to: advanced stage heart disease (e.g., New York Heart Association [NYHA] Class IV), severe lung disease (e.g., severe pulmonary hypertension [WHO Class IV]), severe liver function injury, severe renal disease (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2 or chronic kidney disease [CKD] Stage 4 or dialysis patients), unstable thrombus, other hematologic system diseases (e.g., chronic anemia unrelated to PNH), and deemed unsuitable for study participation by the investigator;
- •Pregnant or lactating women, or those with a positive pregnancy test;
- •Known or suspected immunodeficiency diseases or hereditary complement deficiency at screening;
- •A history of Neisseria meningitidis infection
研究者
研究点 (1)
Loading locations...
相似试验
Enrolling By Invitation
3 期
Open-Label Safety Study of AXS-14 in Subjects With FibromyalgiaFibromyalgiaNCT07637162Axsome Therapeutics, Inc.300
招募中
3 期
An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid SyndromeNCT07593391Neuren Pharmaceuticals Limited180
招募中
2 期
A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant TumorsNCT07448922Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.280
招募中
1 期
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid TumorsNCT07298772Suzhou Suncadia Biopharmaceuticals Co., Ltd.198
招募中
3 期
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb SpasticityNCT07478822Chongqing Claruvis Pharmaceutical Co., Ltd.300